(Q33370836)

26 July 2017

1 reference

title

Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action (English)

1 reference

26 July 2017

1 reference

1 reference

1 reference

Pescovitz MD

1

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 May 2006

1 reference

American Journal of Transplantation

26 July 2017

published in

1 reference

26 July 2017

volume

6

1 reference

26 July 2017

issue

5 Pt 1

1 reference

26 July 2017

page(s)

859-866

1 reference

Humoral transplantation antibodies

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

Humoral theory of transplantation: mechanism, prevention, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

B lymphocyte depletion therapy with rituximab in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

New crossmatch technique eliminates interference by humanized and chimeric monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

21 January 2018

Marginal zone B cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

B cell superantigens: a microbe's answer to innate-like B cells and natural antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

Reactivation of hepatitis B virus with rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

Posttransplant lymphoma--a single-center experience of 500 liver transplantations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

Rituximab and other emerging monoclonal antibody therapies for lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

Reversal of steroid- and anti-lymphocyte antibody-resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

Long-lived plasma cells: a mechanism for maintaining persistent antibody production

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

Humoral immunity due to long-lived plasma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

Maintenance of serological memory by polyclonal activation of human memory B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

Role of B cells as antigen-presenting cells in vivo revisited: antigen-specific B cells are essential for T cell expansion in lymph nodes and for systemic T cell responses to low antigen concentrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

Association of CD20+ infiltrates with poorer clinical outcomes in acute cellular rejection of renal allografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

The role of APRIL and BAFF in lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

Molecules involved in T-B co-stimulation and B cell homeostasis: possible targets for an immunological intervention in autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

Successful treatment with rituximab of lymphoproliferative disorder in a child after cardiac transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

Successful treatment of posttransplant lymphoproliferative disease with prolonged rituximab treatment in intestinal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

Anti-CD20 monoclonal antibody (Rituximab) treatment for Epstein-Barr virus-associated, B-cell lymphoproliferative disease in pediatric liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

The use of rituximab, anti-CD20 monoclonal antibody, in pediatric transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

New strategy for ABO-incompatible living donor liver transplantation with anti-CD20 antibody (rituximab) and plasma exchange

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

Preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy and DFPP-enabled non-responders to undergo ABO-incompatible kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

Successful use of anti-CD20 monoclonal antibody (rituximab) for ABO-incompatible living-related liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

ABO incompatible high-titer renal transplantation without splenectomy or anti-CD20 treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

Rituximab as treatment for refractory kidney transplant rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2006.01288.X

10.1111/J.1600-6143.2006.01288.X

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference